Policy
Britain's life sciences sector is a genuine world-leading asset. Marc believes it is being squandered by slow decision-making, fragmented data infrastructure, and a political culture that has ceded the NHS argument to Labour by default.
Marc has spent his career inside the systems that the NHS depends on. He has led clinical trials, developed diagnostic tools that are now used in NHS pathways, and watched at close quarters as genuinely transformative innovations stall at the point of adoption because of slow NICE decisions, procurement inertia, and a lack of joined-up thinking between the NHS, MHRA, and the life sciences industry. He knows exactly where the bottlenecks are, because he has spent years trying to navigate them.
His position is straightforward: the Conservative Party has allowed Labour to own the NHS argument by retreating into a defensive crouch. The answer is not to concede the ground but to make the case, loudly and specifically, for what a productivity-focused, innovation-led approach to the NHS actually looks like in practice.
That means faster NICE appraisals for diagnostics and medicines with strong evidence bases. It means a serious national strategy for NHS data infrastructure that enables AI tools to be deployed at scale. It means treating the life sciences industry as a strategic national asset rather than a lobby group to be managed. And it means being honest with the public that a health service of this scale cannot be sustained without meaningful reform of how it commissions, adopts, and pays for new treatments.
Marc intends to be one of the Conservative voices making that argument in Westminster, drawing on direct professional experience rather than theoretical policy positions.